Trial reportPhytotherapy research : PTR2014
IQP-GC-101 reduces body weight and body fat mass: a randomized, double-blind, placebo-controlled study.
Trial report in Phytotherapy research : PTR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- The effects of Garcinia cambogia on glycaemic control and liver enzymes in adults: a systematic review and meta-analysis of randomised controlled trials.Journal of nutritional science · 2025Pooled it
- A Systematic Review of Dietary Supplements and Alternative Therapies for Weight Loss.Obesity (Silver Spring, Md.) · 2021Pooled it
- Chinese Herbal Medicine for Weight Management: A Systematic Review and Meta-Analyses of Randomised Controlled Trials.Journal of obesity · 2021Pooled it
- Effect of StandardizedNutrients · 2022Trial
- Trial
- Herbal Medicines for Weight Loss and Lipid Profile Improvement: A Scoping Review of Therapeutic Effects and Safety.Phytotherapy research : PTR · 2025Article
- Effect of β-Caryophyllene on PPAR-γ, NF-κB, and CNR2: Implications for Gut-Brain Axis Communication in a Murine Model of Diet-Induced Obesity.Metabolites · 2025Article
- Clinically Effective Molecules of Natural Origin for Obesity Prevention or Treatment.International journal of molecular sciences · 2024Review
- Review
- Article
- The Effects and Safety of Chinese Herbal Medicine on Blood Lipid Profiles in Placebo-Controlled Weight-Loss Trials: A Systematic Review and Meta-Analysis.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- The Probiotic StrainNutrients · 2021Article
- Risks Associated with the Use of Garcinia as a Nutritional Complement to Lose Weight.Nutrients · 2021Review
- Antiobesity effects of seedlac and shellac in rats fed with a high-fat diet.Research in pharmaceutical sciences · 2020Article
- Determination of Total Chlorogenic Acids in Commercial Green Coffee Extracts.Journal of medicinal food · 2019Article
- Zinc supplementation improves body weight management, inflammatory biomarkers and insulin resistance in individuals with obesity: a randomized, placebo-controlled, double-blind trial.Diabetology & metabolic syndrome · 2019Article
- Body Composition Changes in Weight Loss: Strategies and Supplementation for Maintaining Lean Body Mass, a Brief Review.Nutrients · 2018Review
- Potential roles ofJournal of advanced pharmaceutical technology & researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IQP-GC-101 is a patented blend of the standardized extracts of Garcinia cambogia, Camellia sinensis, unroasted Coffea arabica, and Lagerstroemia speciosa. These individual ingredients of IQP-GC-101 have each shown promise in promoting weight loss; however, the efficacy of the blend has not been established. This randomized, placebo-controlled, double-blind, parallel group study conducted over 14 weeks (including a 2-week run-in phase) aimed to investigate the efficacy and safety of IQP-GC-101 in reducing body weight and body fat mass in overweight Caucasian adults. Subjects took three IQP-GC-101 or placebo tablets, twice a day, 30 min before main meals. All subjects also adhered to a 500 kcal/day energy deficit diet with 30% of energy from fat. Ninety-one overweight and mildly obese subjects (46 in the IQP-GC-101 group, 45 in the placebo group) completed the study. After 12-week intervention, IQP-GC-101 resulted in a mean (±SD) weight loss of 2.26 ± 2.37 kg compared with 0.56 ± 2.34 kg for placebo (pU = 0.002). There was also significantly more reduction in body fat mass, waist circumference, and hip circumference in the IQP-GC-101 group. No serious adverse events were reported. The use of IQP-GC-101 has been shown to result in body weight and body fat reduction in the current study, with good tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.